LyGenesis
- Biotech or pharma, therapeutic R&D
LyGenesis is transforming organ transplantation through a cell therapy platform that enables the growth of functioning ectopic organs in lymph nodes. Our lead program for end-stage liver disease is in Phase 2a trials and enables a single donor liver to treat multiple patients—creating scale, efficiency, and software-like margins. The cell therapy is minimally invasive and lowers risk compared to whole organ transplant. With pipeline programs in pancreas, kidney, and thymus, we’re positioned to redefine regenerative medicine.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}